Respiratory syncytial virus infectious disease

This study tested a nasal spray RSV vaccine in nearly 1,000 healthy infants and toddlers aged 6 to 22 months. The goal was to see if a lower dose works as well as the standard dose and to check safety across different doses. The trial was ended early, so final results are not ava…

This early-stage trial tests an experimental RSV vaccine called CodaVax-RSV, given as nose drops, in healthy children aged 6 months to 5 years. The study evaluates the vaccine's safety and the immune response it triggers. Some children receive the vaccine at different doses, whil…

This study tested an experimental RSV vaccine given to healthy infants at 6 and 12 months old alongside their regular vaccines. The goal was to see if the RSV vaccine still worked well when given at the same time. About 2,200 babies took part, but the study was stopped early.

This phase 3 study tested an intranasal RSV vaccine in about 6,300 healthy children aged 6 to 22 months. The goal was to see if two doses of the nasal spray could prevent lower respiratory tract infections caused by RSV. The trial was terminated early, so final results are not av…

This phase 2 study tests whether an oral antiviral pill called obeldesivir can safely shorten RSV symptoms in adults who are not hospitalized but are at higher risk for severe disease (e.g., those aged 60+ or with chronic lung conditions). Participants take the pill or a placebo,…

This study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if…

This study tested the safety and dosing of sisunatovir, an experimental antiviral drug, in infants and children up to 5 years old with RSV lower respiratory tract infection. Ten participants received either the drug or a placebo. The goal was to find the right dose for future stu…

This study tested an oral drug called sisunatovir for treating RSV in adults who were not hospitalized but had a high risk of severe illness. Participants took either the drug or a placebo for 5 days. The study was terminated early, so results are limited.

This study tested an oral antiviral drug called obeldesivir in children from birth to under 5 years old who had RSV infection. The goal was to see if the drug is safe and helps reduce symptoms faster. However, the trial was stopped early and only enrolled 4 participants, so the r…

Researchers are studying adults with COPD who go to the emergency room or day hospital for sudden worsening of their breathing. The study checks how many of these patients test positive for respiratory syncytial virus (RSV) during the RSV season, from October to April. They compa…